{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:38:11Z","timestamp":1773283091642,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13256-018-1934-2","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T14:22:56Z","timestamp":1548253376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cure of recurring Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae septic shock episodes due to complicated soft tissue infection using a ceftazidime and avibactam-based regimen: a case report"],"prefix":"10.1186","volume":"13","author":[{"given":"Giustino","family":"Parruti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Frattari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ennio","family":"Polilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Savini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonina","family":"Sciacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusta","family":"Consorte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella Concetta","family":"Cibelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Agostinone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Masi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Pieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Cacciatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Di Iorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Fazii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tullio","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"issue":"7","key":"1934_CR1","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1093\/jac\/dkv086","volume":"70","author":"M Tumbarello","year":"2015","unstructured":"Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P, ISGRI-SITA (Italian Study Group on Resistant Infections of the Societ\u00e0 Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133\u201343.","journal-title":"J Antimicrob Chemother"},{"key":"1934_CR2","doi-asserted-by":"crossref","unstructured":"Conte V, Monaco M, Giani T, D\u2019Ancona F, Moro ML, Arena F, D\u2019Andrea MM, Rossolini GM, Pantosti A; AR-ISS Study Group on Carbapenemase-Producing K. pneumoniae. Molecular epidemiology of KPC-producing Klebsiella pneumoniae from invasive infections in Italy: increasing diversity with predominance of the ST512 clade II sublineage. J Antimicrob Chemother. 2016;71(12):3386\u20133391.","DOI":"10.1093\/jac\/dkw337"},{"issue":"Suppl 6","key":"1934_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1469-0691.2008.02123.x","volume":"14","author":"M Ca\u00ednzos","year":"2008","unstructured":"Ca\u00ednzos M. Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections--are they applicable today? Clin Microbiol Infect. 2008;14(Suppl 6):9\u201318.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"1934_CR4","doi-asserted-by":"publisher","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883\u201317. \n                    https:\/\/doi.org\/10.1128\/AAC.00883-17\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1934_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/QCO.0000000000000109","volume":"27","author":"PI Rafailidis","year":"2014","unstructured":"Rafailidis PI, Falagas ME. Options for treating carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2014;27(6):479\u201383.","journal-title":"Curr Opin Infect Dis"},{"issue":"10","key":"1934_CR6","doi-asserted-by":"publisher","first-page":"6605","DOI":"10.1128\/AAC.01165-15","volume":"59","author":"RM Humphries","year":"2015","unstructured":"Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate. Antimicrob Agents Chemother. 2015;59(10):6605\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1934_CR7","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1517\/13543784.2015.1062873","volume":"24","author":"DP Nicolau","year":"2015","unstructured":"Nicolau DP. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opin Investig Drugs. 2015;24(9):1261\u201373.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"1934_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clinthera.2016.01.018","volume":"38","author":"R Sharma","year":"2016","unstructured":"Sharma R, Park TE, Moy S. Ceftazidime-Avibactam: A Novel Cephalosporin\/\u03b2-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Clin Ther. 2016;38(3):431\u201344.","journal-title":"Clin Ther"},{"issue":"4","key":"1934_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2147\/tcrm.2006.2.4.401","volume":"2","author":"DN Fish","year":"2006","unstructured":"Fish DN. Meropenem in the treatment of complicated skin and soft tissue infections. Ther Clin Risk Manag. 2006;2(4):401\u201315.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"1934_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ccc.2009.08.004","volume":"25","author":"A Kumar","year":"2009","unstructured":"Kumar A. Optimizing antimicrobial therapy in sepsis and septic shock. Crit Care Clin. 2009;25(4):733\u201351. viii","journal-title":"Crit Care Clin"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1934-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-018-1934-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1934-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T01:21:42Z","timestamp":1579656102000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-018-1934-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1934"],"URL":"https:\/\/doi.org\/10.1186\/s13256-018-1934-2","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"assertion":[{"value":"16 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Compassionate use of ceftazidime\/avibactam combination for our patient was approved by the local Ethics Committee \u201cRegione Abruzzo, Comitato Etico per la ricerca biomedica delle provicie di Chieti e Pescara.\u201d","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"20"}}